Technical Analysis for SNPX - Synaptogenix, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | -0.67% | |
Doji - Bullish? | Reversal | -0.67% | |
Down 3 Days in a Row | Weakness | -0.67% | |
Gapped Down | Weakness | -0.67% | |
Fell Below 20 DMA | Bearish | -3.74% | |
MACD Bearish Centerline Cross | Bearish | -3.74% |
Alert | Time |
---|---|
Up 1% | about 22 hours ago |
Down 3% | 2 days ago |
Fell Below Previous Day's Low | 2 days ago |
Down 2 % | 2 days ago |
Down 1% | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 02/28/2024
Synaptogenix, Inc. Description
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Multiple Sclerosis Neurodegenerative Diseases Stroke Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.775 |
52 Week Low | 2.72 |
Average Volume | 32,286 |
200-Day Moving Average | 4.19 |
50-Day Moving Average | 3.22 |
20-Day Moving Average | 3.10 |
10-Day Moving Average | 3.19 |
Average True Range | 0.22 |
RSI (14) | 43.82 |
ADX | 20.86 |
+DI | 21.34 |
-DI | 16.07 |
Chandelier Exit (Long, 3 ATRs) | 3.05 |
Chandelier Exit (Short, 3 ATRs) | 3.41 |
Upper Bollinger Bands | 3.49 |
Lower Bollinger Band | 2.72 |
Percent B (%b) | 0.31 |
BandWidth | 24.88 |
MACD Line | -0.03 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0124 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.08 | ||||
Resistance 3 (R3) | 3.09 | 3.06 | 3.06 | ||
Resistance 2 (R2) | 3.06 | 3.03 | 3.06 | 3.05 | |
Resistance 1 (R1) | 3.01 | 3.02 | 3.00 | 3.00 | 3.04 |
Pivot Point | 2.99 | 2.99 | 2.98 | 2.98 | 2.99 |
Support 1 (S1) | 2.93 | 2.96 | 2.92 | 2.92 | 2.88 |
Support 2 (S2) | 2.91 | 2.94 | 2.90 | 2.87 | |
Support 3 (S3) | 2.86 | 2.91 | 2.86 | ||
Support 4 (S4) | 2.84 |